Ardigen Biomedical Imaging Unit enables the identification of small molecule drug candidates through its AI Technology Platform. The Platform integrates the most recent advancements in AI (computer vision and cheminformatics) with molecular biology and medicinal chemistry, bridging the gap between cell imaging and small molecule design. Our unique approach of combining molecular structures, high content screening (HCS) images, and omics data allows us to obtain reliable predictions of Modes of Action and other molecular properties, identify HCS hits, and predict hit candidates. Moreover, its generative component enables fast library design and accelerates the process of lead optimization.
Our solution will improve your drug design process through seamless AI-lab integration. The AI platform is a comprehensive solution that fits into your drug discovery process and can be used out-of-the-box in every step of the process. We can increase your chances of obtaining a drug candidate that will successfully pass the clinical trials. Whether you are just starting your project and looking for compounds to screen, or if you have already gathered phenotypic screening outcomes, we can help.
With our platform you are able to:
As the standard drug design process is expensive and time-consuming, it can be improved with our AI-based solutions. Our Platform allows you to:
Whether you are just starting or have been in the field for some time, we fit into your needs by providing two approaches to
collaboration. Our out-of-the-box Licensed Virtual Screening Platform gives you access to a cloud-based app as a ready-to-use
solution. Whereas, Our Customized Virtual Screening Service enables integration with your internal data, pipelines, and system to
maximize the utility of its usage.
Licensed Virtual Screening Platform or Customized Virtual Screening Service
We strive to improve accuracy and efficiency of diagnostic and therapeutic procedures by utilizing our biomedical computing competences such as: digital image acquisition, processing, quantitative analysis and artificial intelligence in biomedicine; as well as human-computer-interaction and user experience engineering.
Since 2015, we’ve had the opportunity to execute a variety of exciting and complex projects, both for our clients and internally.
A high degree of trust and confidentiality is the foundation for our business. That’s why we are always very excited to share the results of our scientific projects.
We publish and present materials, such as journal publications, posters, case studies and technical notes whenever possible, through which we aim to show the scope of our scientific team’s experience.
